“Ozempic babies” is a term used online to describe unexpected pregnancies reported by people taking Ozempic (semaglutide). Ozempic belongs to a class of medications called GLP-1 receptor agonists, originally developed to treat type 2 diabetes but now widely used for weight loss because they reduce appetite and slow stomach emptying.
As the drug’s popularity has grown, some users have reported becoming pregnant while taking it. Researchers believe this may happen because weight loss and improved metabolic health can restore ovulation and improve fertility, particularly in people with conditions like PCOS.
This article explains what Ozempic does in the body, why surprise pregnancies may occur, and what current research says about using semaglutide around conception.
How obesity and metabolic health influence fertility
Obesity can affect a woman’s reproductive health in many ways. Women with obesity are more likely to experience:
-
- irregular periods
- problems with ovulation
- Infertility
- difficulty with fertility treatments
- Miscarriages
- pregnancy complications
One reason this happens is because excess body fat changes how hormones work in the body. Fat tissue converts some male hormones into estrogen, which can disrupt the normal balance of reproductive hormones.
At the same time, many women with obesity develop insulin resistance, meaning their bodies produce too much insulin. High insulin levels can increase male-type hormones (androgens), which can interfere with ovulation. Other hormone changes also occur. Levels of proteins that regulate hormones, such as sex hormone-binding globulin (SHBG) and some growth-related proteins, tend to decrease, while leptin, a hormone linked to body fat, increases.
These changes disturb the communication between the brain and the ovaries, known as the hypothalamic-pituitary-gonadal (HPG) axis. When this system is disrupted, ovulation may not occur normally.
Because of these hormonal changes, women with obesity often have lower chances of successful implantation and pregnancy. They may also face a higher risk of miscarriage and pregnancy complications, which can make it harder to carry a pregnancy to term and deliver a healthy baby.
What’s an ‘Ozempic Baby’?
“Ozempic baby” is an informal term used online to describe unexpected pregnancies in women who were taking Ozempic or similar GLP-1 drugs.
Ozempic itself is not a fertility drug, but several factors may explain these surprise pregnancies:
1. Weight loss can restore ovulation
Significant weight loss can improve ovulation and menstrual regularity. In a prospective study of 27 obese women with PCOS who received low-dose semaglutide injections, participants lost an average of 7.6 kg (16.8 lbs) and reduced body mass index by 3.1 kg/m² after three months.
By six months, the average weight loss was 11.5 kg (25.4 lbs), and 80% of responsive patients regained normal menstrual cycles. Fasting insulin and insulin-resistance scores improved as well.
Another trial in overweight or obese women with PCOS compared metformin alone with metformin plus semaglutide. After 16 weeks, the combination group lost 6.09 kg (13.4 lbs) versus 2.25 kg (5 lbs) with metformin alone.
The combination therapy also resulted in a 72.5% rate of menstrual recovery versus 42.3% in the metformin group. After treatment was stopped, the natural pregnancy rate was higher in the metformin+semaglutide group (35% vs. 15%).
These results suggest that weight loss facilitated by semaglutide can normalize hormone levels and ovulation in many women with PCOS.
2. Hormone balance may improve
Most experts believe semaglutide improves reproductive hormones mainly through weight loss and improved insulin sensitivity, although researchers are investigating whether GLP-1 drugs may also influence reproductive hormones directly.
In a 12-week study, women with PCOS who took semaglutide had lower levels of certain male hormones (androgens), specifically androstenedione and free testosterone. High androgen levels are common in PCOS and can cause symptoms like irregular periods, acne, excess hair growth, and ovulation problems.
At the same time, the researchers saw an increase in SHBG, a protein that binds to testosterone and reduces the amount of active testosterone in the body. When SHBG levels rise, less testosterone is available to affect tissues, which helps improve symptoms of hyperandrogenism (excess male hormones).
The findings are consistent with earlier research showing that other GLP-1 medications, such as exenatide and liraglutide, can also lower androgen levels in women with PCOS.
In men, losing weight and reducing insulin resistance may also improve sperm quality, which may also contribute to an increased chance of pregnancy.
3. Ozempic and birth control
Because semaglutide slows gastric emptying, some experts worry that it might reduce the absorption of oral contraceptives. A 2024 review found that GLP-1 medications may slightly change how birth control pills are absorbed. However, the overall amount of hormone the body receives stays the same, meaning the effectiveness of the contraceptive pill is not significantly affected, and dose changes are not needed.
Despite this reassuring data, clinicians often suggest using long-acting reversible contraception or barrier methods to ensure effective pregnancy prevention while taking semaglutide.
Dr. Deidre McIntosh, an obstetrician-gynecologist, quoted in a Cleveland Clinic article, advises using a backup form of contraception, such as condoms or a vaginal diaphragm, during dose escalation to avoid unplanned pregnancy.
Dr. McIntosh also suggests considering contraceptive methods less likely to be affected by GLP-1 medications, such as:
-
- IUDs, including hormonal IUDs and the copper IUD
- Contraceptive implants, such as Nexplanon
- Vaginal rings, including NuvaRing, EluRyng, or Annovera
Is Ozempic safe during pregnancy?
Evidence suggests that only very small amounts of semaglutide may cross the placenta. Because the molecule is relatively large (approximately 4100 g/mol), it does not pass easily from the mother’s bloodstream to the baby compared with smaller drugs.
However, animal studies have shown reduced fetal weight, delayed skeletal development, and visceral abnormalities when pregnant rats are exposed to GLP1-agonists. Because of these findings and a lack of human data, the Ozempic label instructs patients to stop the medication at least two months before trying to conceive.
MotherToBaby, an organization providing evidence-based information on medication use in pregnancy, also recommends discontinuing semaglutide two months in advance and emphasizes that it takes about six weeks for the drug to leave the body.
Studies on semaglutide exposure in early pregnancy
Limited human data exist on the effects of semaglutide during pregnancy. A Danish cohort study published in 2025 examined 104,422 singleton pregnancies, of which 32 were exposed to semaglutide during the first trimester. The analysis compared these pregnancies with over 547 insulin-exposed and more than 103,000 unexposed pregnancies.
Semaglutide exposure was not associated with an increased risk of major malformations. However, compared with unexposed pregnancies, semaglutide users had higher rates of:
-
- preterm birth
- large-for-gestational-age infants
- neonatal hypoglycemia
- jaundice
Although these risks were similar to those in women using insulin.
Another large cohort study by the International Pregnancy Safety Study (InPreSS) Consortium evaluated more than 50,000 pregnancies in women with type 2 diabetes who used second-line antidiabetic medications around conception. Compared with insulin, using GLP-1 receptor agonists around the time of conception did not show a higher risk of major birth defects. However, researchers say more studies are still needed to confirm the long-term safety.
Can you take Ozempic while breastfeeding?
It is not yet known whether Ozempic passes into human breast milk. It’s best to talk with your healthcare provider about the best feeding option while using the medication.
Animal studies show that semaglutide can pass into milk, but the levels in rat milk were 3 to 12 times lower than in the mother’s blood.
A small human study examined breast milk samples from eight women who took semaglutide. Researchers collected milk at 0, 12, and 24 hours after dosing, and no semaglutide was detected in any of the samples. Even in a worst-case estimate, the relative infant dose was about 1.26%, which is well below the 10% safety threshold generally considered acceptable for breastfeeding medications. However, researchers say more studies are still needed to confirm long-term safety.
Nonetheless, because of the limited data and the potential for gastrointestinal side effects in newborns, healthcare providers generally recommend avoiding Ozempic while breastfeeding unless the potential benefits outweigh the unknown risks.
Preconception planning and avoiding surprise pregnancies
Ozempic and other GLP-1 medications stay in the body for weeks, so doctors recommend taking certain precautions before trying to conceive.
Talk with your healthcare provider
If you are considering pregnancy and are using Ozempic, discuss your plans with your doctor. They may recommend stopping the medication at least eight weeks (two months) before trying to conceive. Because semaglutide remains in the body for several weeks, this washout period ensures that little to no drug is present during organ development in early pregnancy.
If you’re using the medication for diabetes, your clinician may switch therapy to insulin or metformin.
Use reliable contraception
While taking semaglutide, it is important to use reliable contraception if pregnancy is not desired. Even though a pharmacokinetic review found no significant reduction in contraceptive hormone exposure, clinicians often recommend long-acting reversible methods such as intrauterine devices, hormonal implants, or vaginal rings.
Barrier methods like condoms can also serve as a backup. Using two forms of contraception may provide extra protection during dose adjustments.
Consider alternative weight-loss strategies
If you wish to become pregnant soon, talk with your doctor about alternative weight-loss strategies that are safer in the context of pregnancy. These might include nutrition counseling, physical-activity programs, or medications that have more established safety records in pregnancy, such as metformin for women with PCOS.
In some cases, bariatric surgery is considered, but it requires careful timing relative to conception.
Bottom line
The popularity of Ozempic has generated buzz about “Ozempic babies,” but the term is somewhat misleading. Semaglutide does not increase fertility. Rather, the weight loss and metabolic improvements it provides can restore ovulation in people whose fertility was impaired by obesity.
Limited data suggest that inadvertent early pregnancy exposure may not cause major birth defects, yet there are signs of more preterm births and neonatal metabolic issues, and animal studies show developmental problems. Because of these uncertainties, healthcare providers recommend stopping Ozempic at least eight weeks before trying to conceive and using reliable contraception during treatment.
If you are considering pregnancy or are concerned about unintended conception while using Ozempic, speak with your doctor. They can help you balance weight management, blood sugar control, and reproductive goals safely.
Frequently Asked Questions
Related Articles
Sources
Carmina, E., & Longo, R. A. (2023). Semaglutide Treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. Journal of Clinical Medicine, 12(18), 5921. https://doi.org/10.3390/jcm12185921
Chen, H., Lei, X., Yang, Z., Xu, Y., Liu, D., Wang, C., & Du, H. (2025). Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial. Reproductive Biology and Endocrinology, 23(1), 108. https://doi.org/10.1186/s12958-025-01447-3
Jensterle, M., Ferjan, S., Ležai?, L., So?an, A., Gori?ar, K., Zaletel, K., & Janez, A. (2022). Semaglutide delays 4?hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obesity and Metabolism, 25(4), 975–984. https://doi.org/10.1111/dom.14944
Abdalla, M. A., Deshmukh, H., Atkin, S., & Sathyapalan, T. (2021). The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Therapeutic Advances in Endocrinology and Metabolism, 12, 2042018821989238. https://doi.org/10.1177/2042018821989238
Clinic, C. (2025, March 10). ‘Ozempic Babies’: How GLP-1 agonists affect fertility. Cleveland Clinic. https://health.clevelandclinic.org/ozempic-babies
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024). Drug-Drug Interactions between Glucagon-Like Peptide 1 receptor agonists and oral medications: a systematic review. Drug Safety, 47(5), 439–451. https://doi.org/10.1007/s40264-023-01392-3
Da? ZÖ, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015 Jun 1;16(2):111-7. doi: 10.5152/jtgga.2015.15232. PMID: 26097395; PMCID: PMC4456969. https://pmc.ncbi.nlm.nih.gov/articles/PMC4456969/
Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023). Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Frontiers in Endocrinology, 14, 1215356. https://doi.org/10.3389/fendo.2023.1215356
MotherToBaby. (2025, December 2). Semaglutide – MotherToBaby. https://mothertobaby.org/fact-sheets/semaglutide/
Kolding, L., Henriksen, J. N., Sædder, E. A., Ovesen, P. G., & Pedersen, L. H. (2025). Pregnancy outcomes after semaglutide exposure. Basic & Clinical Pharmacology & Toxicology, 136(4), e70021. https://doi.org/10.1111/bcpt.70021
Cesta, C. E., Rotem, R., Bateman, B. T., Chodick, G., Cohen, J. M., Furu, K., Gissler, M., Huybrechts, K. F., Kjerpeseth, L. J., Leinonen, M. K., Pazzagli, L., Zoega, H., Seely, E. W., Patorno, E., & Hernández-Díaz, S. (2023). Safety of GLP-1 receptor agonists and other Second-Line antidiabetics in early pregnancy. JAMA Internal Medicine, 184(2), 144. https://doi.org/10.1001/jamainternmed.2023.6663
Diab, H., Fuquay, T., Datta, P., Bickel, U., Thompson, J., & Krutsch, K. (2024). Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk. Nutrients, 16(17), 2886. https://doi.org/10.3390/nu16172886
